Halozyme Therapeutics (NASDAQ:HALO) Given “Buy” Rating at HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $95.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 23.23% from the stock’s previous close.

A number of other research analysts have also issued reports on HALO. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Finally, Morgan Stanley reduced their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $77.09 on Tuesday. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The company has a market cap of $9.14 billion, a PE ratio of 27.73, a P/E/G ratio of 0.32 and a beta of 0.84. The business has a 50-day simple moving average of $72.25 and a two-hundred day simple moving average of $70.27. Halozyme Therapeutics has a fifty-two week low of $55.64 and a fifty-two week high of $82.26.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s revenue was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities analysts expect that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the sale, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. This represents a 33.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $71.75, for a total transaction of $1,435,000.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $55,088,215. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 74,102 shares of company stock valued at $5,205,798. 2.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership grew its position in Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after purchasing an additional 749,484 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Halozyme Therapeutics by 1.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after buying an additional 25,731 shares during the last quarter. Norges Bank purchased a new stake in shares of Halozyme Therapeutics in the fourth quarter worth about $128,201,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics during the fourth quarter worth about $124,031,000. Finally, Federated Hermes Inc. raised its position in Halozyme Therapeutics by 8.5% during the fourth quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock valued at $105,972,000 after acquiring an additional 123,917 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.